A Phase 1/1b Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression (Pancreatic Cancer)
Study of ASP2138 in Patients with Stomach or Pancreatic Cancer
Sponsor: Astellas Pharma Global Development Inc.
Enrolling: Male and Female Patients
IRB Number: AAAU7688
U.S. Govt. ID: NCT05365581
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The goal of this study is to see if a study drug called ASP2138 is safe and effective for people diagnosed with tumors known to have Claudin (CLDN) 18.2 expression. CLDN is a group of proteins seen in gastric-specific, gastroesophageal junction (GEJ) or pancreatic cancer types. The study will also see how ASP2138 is processed in the blood. Each participant will complete a number of procedures and blood collections in order to find the best dose of ASP2138. When this dosage is identified, it will be used to evaluate if ASP2138 causes tumors to shrink. ASP2138 will be assessed continuously throughout the study to understand if it is safe and effective. This study is a first-in-human clinical trial. The Food and Drug Administration (FDA) in the United States of America has not approved ASP2138 for sale or for the treatment of cancer.
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with with stomach or pancreatic cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator